Caroline Palomeque
Stock Analyst at Maxim Group
(2.58)
# 2,217
Out of 4,945 analysts
9
Total ratings
55.56%
Success rate
16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Downgrades: Hold | n/a | $2.07 | - | 2 | Aug 14, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $36.51 | +61.60% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $150.33 | +2.44% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $65.54 | -11.50% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $192.04 | -13.56% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $14.46 | +169.71% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $9.07 | +572.55% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $10.11 | +295.65% | 1 | Jun 23, 2022 |
Daré Bioscience
Aug 14, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.07
Upside: -
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $36.51
Upside: +61.60%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $150.33
Upside: +2.44%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $65.54
Upside: -11.50%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $192.04
Upside: -13.56%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $14.46
Upside: +169.71%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $9.07
Upside: +572.55%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $10.11
Upside: +295.65%